ELI LILLY & Co (LLY) company profile
Close on Nov 17, 2026Market cap $1.33TP/E 45.9Yield 0.44%
About Eli Lilly
Pharmaceutical Preparations, SIC 2834
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products across a single operating segment. Its portfolio spans therapeutic treatments in cardiometabolic health, oncology, immunology, and neuroscience, addressing conditions such as diabetes, obesity, various cancers, and autoimmune disorders. The company provides its therapies to patients globally, distributing primarily through wholesale distributors, retail pharmacies, and hospitals, while engaging directly with healthcare professionals and consumers via platforms such as LillyDirect.
The enterprise operates manufacturing and distribution facilities across the United States, Puerto Rico, Europe, and Asia. It markets and commercializes its medical therapies in approximately 90 countries worldwide. The company traces its origins to Indianapolis, Indiana, where its predecessor drug manufacturing business was initially established and where its corporate headquarters remain situated.
Summary of the business section of Eli Lilly's latest annual report, written by StockData.
Company profile
Company
- Legal name
- ELI LILLY & Co
- Founded
- 1876
- Headquarters
- Indianapolis, IN
- Address
- Lilly Corporate Ctr, Drop Code 1094 46285
- Phone
- (317) 276-2000
- Website
- www.lilly.com
- Employees
- 50,000, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Indiana
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Indianapolis, Indiana
Stock & identifiers
- Ticker
- LLY
- Exchange
- NYSE
- Shares outstanding
- 941M, Oct 26, 2026
- Public float
- $807.89B, Jun 30, 2025
- Filer category
- Large accelerated filer
- Stock splits
- 2-for-1, Oct 16, 1997; 2-for-1, Dec 21, 1995; 2-for-1, May 1, 1989; 2-for-1, Jan 30, 1986
- SEC CIK
- 59478
- CUSIP
- 532457108
- ISIN
- US5324571083
- FIGI
- BBG000BNBDC2
- Share class FIGI
- BBG001S5STL8
- LEI
- FRDRIPF3EKNDJ2CQJL29
- EIN
- 35-0470950
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| David A. Ricks | President, Chair, and CEO, Director | 685,273 |
| Patrik Jonsson | EVP & President, LLY Int'l | 54,075 |
| Eric Dozier | EVP, Chief People Officer | 15,933 |
| Anat Hakim | EVP, GC & Secretary | 45,562 |
| Edgardo Hernandez | EVP & Pres., Mfg. Operations | 48,364 |
| Daniel Skovronsky | EVP, CS&PO & Pres. LRL | 235,569 |
| Lucas Montarce | EVP & CFO | 17,191 |
| Adrienne S. Brown | EVP, President LLY Imm | 9,894 |
| Kenneth L. Custer | EVP & President, Card Met Hlth | 11,935 |
| Melissa Seymour | EVP, Global Quality | 1,038 |
| Donald A. Zakrowski | SVP, Finance, & CAO | 3,261 |
| Ilya Yuffa | EVP&Pres, LLY USA&Global Capab | 29,804 |
| Diogo Rau | EVP & CIDO | 26,397 |
| Naarden Jacob Van | EVP,Pres LLY Oncology&HdCorpBD | 36,271 |
| Carole Ho | EVP & Pres, Lilly Neuroscience | – |
| Anne E. White | EVP & Pres, Lilly Neuroscience | 74,210 |
| Katherine Baicker | Director | 23,815 |
| Gabrielle Sulzberger | Director | 3,188 |
| Juan R. Luciano | Director | 17,148 |
| J. Erik Fyrwald | Director | 75,719 |
| Jon R. Moeller | Director | 473 |
| Mary Lynne Hedley | Director | 2,528 |
| Ralph Alvarez | Director | 56,783 |
| William G. Kaelin Jr | Director | 22,139 |
| Kimberly H. Johnson | Director | 3,452 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $36.70M | $75.19M | $10.93M | $671 | $154 |
| FY2024 | $29.24M | $80.58M | $6.09M | $478 | $123 |
| FY2023 | $26.57M | $120.87M | $7.84M | $359 | $118 |
| FY2022 | $21.40M | $64.09M | $5.77M | $223 | $125 |
| FY2021 | $21.51M | $75.71M | $4.73M | $166 | $117 |
| FY2020 | $23.71M | $51.25M | $6.79M | $131 | $102 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| David A. Ricks Chair, President, and Chief Executive Officer | $1.70M | $23.33M | $6.49M | $5.19M | $36.70M | +25% |
| Lucas Montarce Executive Vice President and Chief Financial Officer | $1.00M | $5.00M | $2.18M | $303.32K | $8.48M | +188% |
| Daniel M. Skovronsky, M.D., Ph.D. Executive Vice President, Chief Scientific and Product Officer and President, Lilly Research Labs | $1.49M | $12.00M | $3.25M | $1.05M | $17.79M | +41% |
| Anat Hakim Executive Vice President, General Counsel and Secretary | $1.00M | $6.00M | $2.18M | $665.52K | $9.85M | +32% |
| Jake Van Naarden Executive Vice President and President, Lilly Oncology and Head of Corporate Business Development | $920.19K | $4.50M | $2.01M | $159.89K | $7.59M | +31% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Employees
Headcount reported in annual reports
“At the end of 2025, we employed approximately 50,000 people, including approximately 27,000 employees outside the U.S.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?